Last reviewed · How we verify
Ruxolitinib Oral Tablet [Jakafi]
Ruxolitinib Oral Tablet [Jakafi] is a Small molecule drug developed by Oncotherapeutics. It is currently in Phase 1 development. Also known as: Ruxolitinib, Jakavi, Ruxolitinib, Jakafi.
At a glance
| Generic name | Ruxolitinib Oral Tablet [Jakafi] |
|---|---|
| Also known as | Ruxolitinib, Jakavi, Ruxolitinib, Jakafi |
| Sponsor | Oncotherapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruxolitinib Oral Tablet [Jakafi] CI brief — competitive landscape report
- Ruxolitinib Oral Tablet [Jakafi] updates RSS · CI watch RSS
- Oncotherapeutics portfolio CI
Frequently asked questions about Ruxolitinib Oral Tablet [Jakafi]
What is Ruxolitinib Oral Tablet [Jakafi]?
Ruxolitinib Oral Tablet [Jakafi] is a Small molecule drug developed by Oncotherapeutics.
Who makes Ruxolitinib Oral Tablet [Jakafi]?
Ruxolitinib Oral Tablet [Jakafi] is developed by Oncotherapeutics (see full Oncotherapeutics pipeline at /company/oncotherapeutics).
Is Ruxolitinib Oral Tablet [Jakafi] also known as anything else?
Ruxolitinib Oral Tablet [Jakafi] is also known as Ruxolitinib, Jakavi, Ruxolitinib, Jakafi.
What development phase is Ruxolitinib Oral Tablet [Jakafi] in?
Ruxolitinib Oral Tablet [Jakafi] is in Phase 1.
Related
- Manufacturer: Oncotherapeutics — full pipeline
- Also known as: Ruxolitinib, Jakavi, Ruxolitinib, Jakafi
- Compare: Ruxolitinib Oral Tablet [Jakafi] vs similar drugs
- Pricing: Ruxolitinib Oral Tablet [Jakafi] cost, discount & access